Dimetacrine
|  | |
|  | |
| Clinical data | |
|---|---|
| Trade names | Istonil, Istonyl, Linostil, Miroistonil | 
| Routes of administration | Oral | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| IUPAC name 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | 
 | 
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H26N2 | 
| Molar mass | 294.442 g·mol−1 | 
| 3D model (JSmol) | |
| SMILES 
 | |
Dimetacrine (brand names Istonil, Istonyl, Linostil, Miroistonil), also known as dimethacrine and acripramine, is a tricyclic antidepressant (TCA) used in Europe and formerly in Japan for the treatment of depression.[1][2][3][4][5] It has imipramine-like effects; though, in a double-blind clinical trial against imipramine, dimetacrine was found to have lower efficacy in comparison and produced more weight loss and abnormal liver tests.[6][7] Little is known about the pharmacology of dimetacrine, but it can be inferred that it acts in a similar manner to other TCAs. If this is indeed the case, dimetacrine may induce severe cardiac toxicity in overdose (a side effect unique to the tricyclic class of antidepressants).
References
- ↑ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
- ↑ Affective disorders: perspective on ... - Google Books.
- ↑ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 978-3-527-31058-6.
- ↑ Taen S, Pöldinger W (December 1966). "[Dimethacrine (istonil), an acridane derivative with the antidepressive action]". Schweizerische Medizinische Wochenschrift (in German). 96 (48): 1616–20. PMID 6008540.
- ↑ Meyer R (May 1968). "[Contribution to the clinical evaluation of the antidepressive effect of dimethacrine (Istonil)]". Praxis (in German). 57 (20): 721–3. PMID 5756370.
- ↑ Abuzzahab FS (November 1973). "A double-blind investigation of dimethacrine versus imipramine in hospitalized depressive states". International Journal of Clinical Pharmacology, Therapy and Toxicology. 8 (3): 244–53. PMID 4149236.
- ↑ Mutschler, Ernst; Derendorf, Hartmut (1995). Drug actions: basic principles and therapeutic aspects. Stuttgart, Germany: Medpharm Scientific Pub. ISBN 0-8493-7774-9. Retrieved January 30, 2013.
| 
 
 
 
 
 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Classes | 
 | 
|---|---|
| Antidepressants (TCAs and TeCAs) | 
 | 
| Antihistamines | 
 | 
| Antipsychotics | 
 | 
| Anticonvulsants | |
| Others | 
 | 
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

